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Association of Naloxone Coprescription Laws With Naloxone
Prescription Dispensing in the United States
Minji Sohn, PhD; Jeffery C. Talbert, PhD; Zhengyan Huang, PhD; Michelle R. Lofwall, MD; Patricia R. Freeman, PhD
Abstract
IMPORTANCE To mitigate the opioid overdose crisis, states have implemented a variety of legal
interventions aimed at increasing access to the opioid antagonist naloxone. Recently, Virginia and
Vermont mandated the coprescription of naloxone for potentially at-risk patients.
OBJECTIVE To assess the association between naloxone coprescription legal mandates and
naloxone dispensing in retail pharmacies.
DESIGN, SETTING, AND PARTICIPANTS This was a population-based, state-level cohort study. The
sample included all prescriptions dispensed for naloxone in the retail pharmacy setting contained in
IQVIA’s national prescription audit, which represents 90% of all retail pharmacies in the United
States. The unit of observation was state-month and the study period was January 1, 2011, to
December 31, 2017.
EXPOSURES State legal intervention mandating naloxone coprescription.
MAIN OUTCOMES AND MEASURES Number of naloxone prescriptions dispensed. State rates of
naloxone prescriptions dispensed per month per 100 000 standard population were calculated.
RESULTS The rate of naloxone dispensing increased after implementation of legal mandates for
naloxone coprescription. An estimated 88 naloxone prescriptions per 100 000 were dispensed in
Virginia and 111 prescriptions per 100 000 were dispensed in Vermont during the first full month the
legal requirement was effective. In comparison, 16 naloxone prescriptions per 100 000 were
dispensed in the 10 states (including the District of Columbia) with the highest opioid overdose death
rates and 6 prescriptions per 100 000 were dispensed in the 39 remaining states. The number of
naloxone prescriptions dispensed was associated with the legal mandate for naloxone coprescription
(incidence rate ratio [IRR], 7.75; 95% CI, 1.22-49.35). Implementation of the naloxone coprescription
mandate was associated with an estimated 214 additional naloxone prescriptions dispensed per
month in the period following the mandates, holding all other variables constant. Among covariates,
naloxone access laws (IRR, 1.37; 1.05-1.78), opioid overdose death rates (IRR, 1.06; 95% CI, 1.04-1.08),
the percentage of naloxone prescriptions paid by third-party payers (IRR 1.009; 1.008-1.010), and
time (IRR, 1.06; 95% CI, 1.05-1.07) were significantly associated with naloxone prescription
dispensing.
CONCLUSIONS AND RELEVANCE These study findings suggest that legally mandated naloxone
prescription for those at risk for opioid overdose may be associated with substantial increases in
naloxone dispensing and further reduction in opioid-related harm.
JAMA Network Open. 2019;2(6):e196215. doi:10.1001/jamanetworkopen.2019.6215
Key Points
Question Are legal mandates for
naloxone coprescription associated with
increases in naloxone prescription
dispensing?
Findings In this population-based,
state-level cohort study using data from
retail pharmacies in all 50 states and the
District of Columbia, having a legal
mandate for naloxone coprescription
was associated with approximately 7.75
times more dispensed naloxone
prescriptions compared with not having
the requirements. This equates to an
estimated 214 additional naloxone
prescriptions dispensed per month in
the period following the mandates,
holding all other variables constant.
Meaning State legal interventions that
mandate naloxone coprescription for
potentially at-risk patients may be
associated with increases in naloxone
prescription dispensing in retail
pharmacies, and this strategy may be
useful to improve naloxone availability
and reduce opioid-related harm.
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Author affiliations and article information are
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Introduction
Deaths due to opioid overdose (OOD) have been continuously increasing over the past 2 decades,
and this trend is predicted to continue.1,2 From 2016 to 2017, the age-adjusted rate of drug overdose
deaths increased by 9.6%, from 19.8 per 100 000 standard population in 2016 to 21.7 per 100 000
in 2017.2 Of all drug overdose deaths, approximately 68% were attributed to opioids in 2017.2 States
have implemented varied approaches to prevent prescription opioid misuse, including mandatory
query of prescription drug monitoring programs prior to issuing opioid analgesic prescriptions and
establishing limits on the quantity and days’ supply of opioid analgesics.3-5 These prescription opioid
supply-side interventions, however, are estimated to be associated with modest decreases in
overdose deaths, as recent data show that the OOD crisis is now mainly driven by illicitly
manufactured synthetics, such as fentanyl.1
A widespread public health response to the OOD crisis has focused on increasing naloxone
access, generally through community-based naloxone programs in which naloxone kits were
distributed by local agencies free of charge.6 Naloxone is a prescription drug that rapidly reverses the
effects of opioids (both natural and synthetic) and is considered an antidote for OOD. Since 2010,
states have made legal changes aimed at expanding access to naloxone and increasing its use by
laypersons.7,8 For example, as of 2017, 49 states and the District of Columbia had enacted a naloxone
access law authorizing pharmacists to dispense or distribute naloxone without a patient-specific
prescription from another medical professional.7 However, recent data show that, despite these legal
interventions, overall naloxone dispensing remains low. For example, using data from Symphony
Health’s Pharmaceutical Audit Suite Prescription Monthly data, Xu et al9 showed that, in 2016, a total
of 147 457 naloxone prescriptions were dispensed from retail pharmacies, which is approximately 46
per 100 000. Similarly, Freeman et al,10 using data from IQVIA’s national prescription audit, reported
widely varying rates of naloxone dispensing between states, ranging from 2.2 per 100 000 in Hawaii
to 244 per 100 000 in Virginia during the second quarter of 2017. In April 2018, the Office of the
Surgeon General issued a public health advisory on naloxone and opioid overdose noting the limited
availability of naloxone in communities and encouraged health care practitioners to play more active
roles in increasing the awareness, possession, and use of naloxone.11,12
An additional public health intervention recommended by several US federal agencies that is
being considered by many states is emphasizing coprescribing or codispensing of naloxone to
patients at risk for OOD. In 2016, the Centers for Disease Control and Prevention published an opioid
prescribing guideline that recommends prescribers consider a naloxone coprescription if a patient’s
opioid dosage exceeds 50 morphine milligram equivalents per day.13 The Substance Abuse and
Mental Health Services Administration also recommended naloxone coprescribing for individuals
with a history of OOD or substance use disorder, those who are taking benzodiazepines with opioids,
and those who are at risk for using a high-dose opioid when they are no longer tolerant (eg, patients
leaving detoxification facilities, jails).14 In 2017, Virginia and Vermont became the first 2 states to
mandate naloxone coprescription to opioid-receiving patients who have risk factors of OOD.15,16 Our
objective for this study was to assess the association between these legally mandated interventions
requiring naloxone coprescription and naloxone dispensing over time.
Methods
This was a population-based, state-level observational cohort study. We assessed the association
between the number of naloxone prescriptions dispensed and the legal requirements for naloxone
coprescription using longitudinal data analysis. The unit of observation was state-month. This study
was deemed not human subjects research by the University of Kentucky Institutional Review Board
and therefore was exempt from institutional review board review and approval. This study followed
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline.
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Outcome
The outcome variable was the number of naloxone prescriptions dispensed. The data came from the
IQVIA national prescription audit and included nationwide all-payer naloxone prescription
transactions in retail pharmacies per month per state from January 1, 2011, to December 31, 2017.17
The national prescription audit reflects nearly 90% of all retail pharmacies in the United States, and
the data are weighted to approximately 100% of all dispensing using the IQVIA weighting methods.17
The data set included information on payment type (eg, third-party coverage or self-pay).
Exposure
The primary exposure of the study was the legal requirements for naloxone coprescription. During
2011-2017, 2 states implemented legal requirements affecting naloxone coprescribing practice.
Virginia was the first state to mandate naloxone prescription for patients with 1 or more risk factors
of OOD, including prior OOD, substance misuse, doses exceeding 120 morphine milligram
equivalents per day, and concomitant benzodiazepine use (regulation effective date March 15,
2017).10 Subsequently, effective July 2017, Vermont required naloxone prescriptions for patients
receiving opioid doses exceeding 90 morphine milligram equivalents per day and those receiving
opioid and benzodiazepine prescriptions concurrently.11 For analysis, an indicator variable was
created in which Virginia and Vermont were categorized as having the legal requirements for
naloxone coprescription from the first calendar month that those requirements were effective
(March and July 2017, respectively).
Covariates
Naloxone Access Laws
Between 2011 and 2017, a number of states adopted laws aimed at increasing the availability of
naloxone to laypersons.7 One of the most common legal interventions instituted authorizes
pharmacists to dispense naloxone without a patient-specific prescription from a physician or other
prescriber, using various mechanisms, such as a standing order or state-wide protocol. Third-party
prescribing laws were also increasingly adopted by which a prescriber can issue a naloxone
prescription to family members, friends, or caregivers of an individual at risk for OOD, who are most
likely to be first responders in the event of an OOD. The data on effective dates of standing orders
and third-party prescribing laws were obtained from the Prescription Drug Abuse Policy System
website.7 In most states, the effective dates of a naloxone standing order and third-party prescribing
law were the same or only a few months apart; therefore, we created a composite indicator variable
to reflect the first calendar month that either the standing order or third-party prescribing law was
effective.
Retail Prescription Opioid Distribution
To adjust for underlying variations in prescription opioid analgesic use between states, we included
the total distributed dose of prescription opioid analgesics in the analysis. Because drugs in the
opioid class have relatively different potencies, opioid analgesic doses were standardized by
morphine milligram equivalent. The data were derived from the Automated Reports and
Consolidated Ordering System (ARCOS), a program operated by the Drug Enforcement
Administration. The ARCOS collects controlled substances transaction reports at the state level from
drug manufacturers and distributors.18 For this study, total grams of prescription opioid analgesics
(excluding buprenorphine) were extracted from the ARCOS before they were converted to morphine
milligram equivalents.19 Buprenorphine was excluded because it is primarily used for medication-
assisted treatment among patients with opioid use disorder.20
Opioid-Involved Overdose Deaths
It is likely that the rate of opioid-related overdose deaths is associated with naloxone dispensing, as
well as state-level regulatory considerations, such as naloxone coprescription mandates. For this
JAMA Network Open | Substance Use and Addiction Naloxone Coprescription Laws and Prescription Dispensing in the United States
JAMA Network Open. 2019;2(6):e196215. doi:10.1001/jamanetworkopen.2019.6215 (Reprinted) June 21, 2019 3/9
Downloaded From: https://jamanetwork.com/ on 06/09/2020
reason, state-specific crude death rates involving opioid-involved overdose for each year were
adjusted in the analysis. Mortality data for US residents for 2011-2017 were obtained from the
National Center for Health Statistics Multiple Cause of Death within the Centers for Disease Control
and Prevention’s Wide-Ranging Online Data for Epidemiologic Research Online Database,21 which is
based on information from death certificates filed in 50 states and the District of Columbia. Drug
overdose deaths involving opioids were identified, in accordance with a previously published Centers
for Disease Control and Prevention report,22 using the International and Statistical Classification of
Diseases, 10th Revision (ICD-10) codes. First, deaths with drug overdose as the underlying cause were
identified using ICD-10 codes of X40 to X44 (unintentional), X60 to X64 (suicide), X85 (homicide),
and Y10 to Y14 (undetermined intent). Of those codes, opioid-related deaths were identified based
on ICD-10 codes of T40.0 to T40.4 and T40.6 (opioids), including those for heroin (T40.1),
prescription opioids (T40.2-40.3), and synthetic opioids, excluding methadone (T40.4).
Percentage of Naloxone Prescriptions Paid for by Third-Party Payers
Even if naloxone is coprescribed with opioids, the patient may choose not to fill the naloxone
prescription if it is not covered by a third-party payer. The list prices of naloxone increased over time
during the study observation period.23 As the prices increase, having third-party coverage for a
naloxone prescription becomes essential for ensuring financial access to the medication. As such,
naloxone dispensing is likely correlated with an individual’s access to coverage for the naloxone
prescription. Therefore, we adjusted for the percentage of naloxone prescriptions paid by third-party
payers, which was obtained from the IQVIA national prescription audit. Third-party payers included
Medicare, Medicaid, and commercial health insurance programs.
Statistical Analysis
Monthly unadjusted rates of naloxone dispensing per 100 000 standard population were estimated.
We compared the trend between 4 groups: (1) Virginia, (2) Vermont, (3) the top 10 states (including
the District of Columbia) with OOD deaths in 2016 (West Virginia, New Hampshire, Ohio, District of
Columbia, Massachusetts, Maryland, Rhode Island, Maine, Connecticut, and Kentucky),21 and (4) all
39 remaining states. We used 2016 estimates to identify the top 10 states (including the District of
Columbia) with OOD deaths to compare baseline differences prior to legal requirements for naloxone
coprescription in 2017.
We used a population-averaged approach to investigate the association between legal
requirements for naloxone coprescription and dispensing.24 Based on the observed overdispersion
in the outcome variable (ie, variance greater than the mean), we calculated a generalized estimating
equation (GEE) using the log-link function and negative binomial distribution.25 We assumed that
the strength of correlation between consecutive measurements within a state would decrease as
measurements become farther apart. For this reason, we specified the working covariance structure
as the first-order autoregressive process. Robust SEs were clustered at the state level. In addition to
the covariates described above, census region (Northeast, Midwest, South, and West) and time,
expressed as the number of months from the beginning of the observation period, were adjusted in
the regression analysis. The natural logarithm of state population was included as an offset term.
Incidence rate ratios (IRRs) with associated 95% CIs and the mean marginal effects were estimated.
To test the robustness of the GEE model results, we used a negative binomial regression with
fixed-effects model to estimate the association between legal requirements for naloxone
coprescription and dispensing. Detailed model specification and results are available in the eMethods
in the Supplement. The results of the fixed-effects model were consistent with the GEE model
results. Statistical significance was set at 2-tailed P < .05. All analyses were performed using Stata/SE,
version 13 (StataCorp).26
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Results
In a descriptive, unadjusted analysis, the rate of naloxone dispensing per 100 000 increased
significantly on the implementation of legal requirements for naloxone coprescription (Figure). An
estimated 88 naloxone prescriptions per 100 000 were dispensed in Virginia and 111 prescriptions
per 100 000 were dispensed in Vermont during the first full month that the legal requirement was
effective (April and July 2017, respectively). Meanwhile, in July 2017, 16 naloxone prescriptions per
100 000 were dispensed in the top 10 states (including the District of Columbia) with OOD deaths
and 6 prescriptions per 100 000 in the remaining states—all without mandated naloxone
prescribing. By December 2017, the dispensing rate per 100 000 decreased to 34 in Virginia and 25
in Vermont.
In the GEE regression model, the number of naloxone prescriptions dispensed was associated
with the legal requirements for naloxone coprescription (IRR, 7.75; 95% CI, 1.22-49.35) (Table). In
particular, implementation of the naloxone coprescription mandates was associated with an
estimated 214 additional naloxone prescriptions dispensed per month in the period following the
mandates, holding other variables constant. Among covariates, naloxone access laws (IRR, 1.37; 95%
CI, 1.05-1.78), OOD death rates (IRR, 1.06; 95% CI, 1.04-1.08), the percentage of naloxone
prescriptions paid by third-party payers (IRR, 1.009; 95% CI, 1.008-1.010), and time (IRR, 1.06; 95%
CI, 1.05-1.07) were significantly associated with naloxone dispensing. The results of the GEE
regression model were robust when compared with estimates from the negative binomial regression
with the fixed-effects model (eTable in the Supplement).
Figure. Naloxone Prescription Dispensing Rates per 100 000 Standard Population, 2011-2017
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Table. Population-Averaged Model for Variables Associated With the Number
of Naloxone Prescriptions Dispensed, 2011-2017a
Variable IRR (95% CI) P Value
Legal mandate for naloxone coprescription 7.75 (1.22-49.35) .03
Third-party prescribing or standing order law 1.37 (1.05-1.78) .02
ln (total MME distributed) 0.92 (0.81-1.05) .21
Crude death rate involving opioid overdose 1.06 (1.04-1.08) <.001
% Naloxone paid by third-party payers 1.009 (1.008-1.010) <.001
Time, mo 1.06 (1.05-1.07) <.001
Region
Northeast 1 [Reference]
Midwest 0.97 (0.62-1.53) .90
South 1.24 (0.77-2.00) .38
West 1.48 (0.92-2.39) .10
ln (population size) 1 (Offset term)
Abbreviations: IRR, incidence rate ratio; MME,
morphine milligram equivalent.
a Generalized estimating equation used.
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Discussion
To mitigate the OOD crisis, states have implemented a variety of legal interventions aimed at
increasing access to the opioid antagonist naloxone. Most recently, Virginia and Vermont mandated
the coprescription of naloxone to potentially at-risk patients, including those with a history of OOD or
receiving high-dose opioids. Our study suggests that legally mandating naloxone prescription for
individuals at high risk for OOD is associated with an increased number of dispensed naloxone
prescriptions. Our descriptive trend analysis suggests that the association is likely sequential, as the
increase in the number of naloxone prescriptions dispensed was observed immediately on
implementation of the legal mandates. In late 2018, similar mandates were enacted in California,
Arizona, and Rhode Island.27 Further evaluation of the association between naloxone prescription
and dispensing in these states with new mandates is now also warranted.
A decline in naloxone prescription dispensing was observed in the last quarter of 2017 in both
Virginia and Vermont. This trend is anticipated to some extent, as the legal mandates for naloxone
coprescription are at the patient level and not the prescription level.15,16 For example, the Vermont
rule specifies that “prescribers shall coprescribe naloxone or document in the medical record that a
patient has a valid prescription for or states they are in possession of naloxone.”15 Thus, it would be
expected that once an initial naloxone coprescription was written and documented in the medical
record, a prescriber would not issue a second naloxone prescription until such time the patient
indicated that they no longer had a valid prescription or were no longer in possession of naloxone.
Currently, data are limited as to when a second naloxone prescription is needed for persons meeting
risk criteria. Our data set included the number of naloxone prescriptions dispensed in retail
pharmacies, which is often less than the number of written prescriptions.28-30
In this study, having enacted either third-party prescribing or standing order laws was
associated with a mean increase of 37% in naloxone dispensing. This result is in agreement with a
recent study published by Xu et al.9 They conducted a longitudinal study using nationally
representative pharmacy dispensing data and reported a 79% increase in naloxone dispensing as
being associated with implementation of either third-party prescribing or standing orders for
naloxone. While both studies report a positive association, the fact that the point estimate of the IRR
reported by Xu et al9 is different from what we found is likely owing to differences in analytical
approach (GEE vs fixed-effect), unit of observation (state-month vs state-quarter), and observation
period (2011-2017 vs 2007-2016).
Particular caution is required when interpreting the IRR of the OOD deaths. The data on
naloxone dispensing and OOD deaths are not temporal, and they do not suggest a sequence of those
events. In other words, although naloxone dispensing increased during the observation period, the
extent to which naloxone dispensing is influenced by OOD overdose deaths or vice versa was not
estimated in this study. Instead, the reported IRR only reflects a positive association between the 2
variables as they occur simultaneously.
While OOD was not examined as an outcome variable in this study, a recently published study
used a quasi-experimental design to demonstrate that harm reduction policy strategies, including
naloxone access laws and overdose Good Samaritan laws, were associated with a significant
reduction in OOD.31 In particular, states with naloxone access laws had an average of 15% lower
incidence of OOD compared with states without those laws. Because these laws directly target
naloxone availability, it is possible to infer that the process of naloxone prescribing and dispensing
serves as an intermediate step for reducing the rate of OOD. We further argue that legal requirements
for naloxone coprescription may have a potentially greater influence on preventing OOD through
increased naloxone access for at-risk individuals.
Limitations
There are limitations to this study. First, the strength of association reported in this study reflects the
short-term assessment of the legal requirements for naloxone coprescription (<10 months). Further
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investigation is needed to evaluate the longer-term association. Second, our naloxone dispensing
data do not include naloxone distributed free of charge through community programs. It is possible
that the distribution of naloxone through such resources varies greatly by state, and as a result, states
distributing a large quantity of naloxone for free appear as dispensing smaller numbers of naloxone
prescriptions. The findings of this study should be applied only to naloxone dispensing in retail
pharmacies. Third, the IQVIA data only report state-level counts of naloxone prescriptions. These
data cannot be used to determine whether naloxone prescriptions were in fact coprescribed with
opioids, since there are no individual-level patient identifiers that can be used to link naloxone and
opioid prescriptions. In addition, these data lack diagnosis codes, such as opioid use disorder, that
would allow determination of whether naloxone prescriptions are being filled by patients with
illnesses at high risk for OOD. These limitations are substantial for the purposes of this analysis.
Conclusions
Public policy efforts aimed at increasing naloxone access have focused on standing-order and third-
party prescribing provisions. Although this study and others have shown these provisions to increase
naloxone access,9 additional efforts are needed if we are to meet the US Surgeon General’s goal of
broadening the availability and use of naloxone to reduce OOD mortality.11,12 Our study findings
suggest that legally mandated naloxone prescription for persons at risk for OOD may increase
naloxone dispensing and further reduce harm and save lives.
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